NASDAQ:NEOS - Neos Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.10 -0.10 (-1.61 %)
(As of 07/20/2018 01:09 AM ET)
Previous Close$6.20
Today's Range$6.05 - $6.25
52-Week Range$5.80 - $13.15
Volume126,200 shs
Average Volume304,525 shs
Market Capitalization$184.13 million
P/E Ratio-2.28
Dividend YieldN/A
Neos Therapeutics logoNeos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older; Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for the treatment of ADHD; and Adzenys ER, an amphetamine XR liquid suspension for the treatment of ADHD. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.

Receive NEOS News and Ratings via Email

Sign-up to receive the latest news and ratings for NEOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio-13.08
Current Ratio1.82
Quick Ratio1.49


Trailing P/E Ratio-2.28
Forward P/E Ratio-3.86
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.02 million
Price / Sales7.07
Cash FlowN/A
Price / CashN/A
Book Value$0.27 per share
Price / Book22.59


EPS (Most Recent Fiscal Year)($2.68)
Net Income$-66,240,000.00
Net Margins-211.13%
Return on Equity-586.25%
Return on Assets-58.31%


Outstanding Shares29,000,000
Market Cap$184.13

Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions

What is Neos Therapeutics' stock symbol?

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics Inc (NASDAQ:NEOS) announced its earnings results on Wednesday, May, 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.02. The business had revenue of $10.73 million for the quarter. Neos Therapeutics had a negative net margin of 211.13% and a negative return on equity of 586.25%. View Neos Therapeutics' Earnings History.

When is Neos Therapeutics' next earnings date?

Neos Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Neos Therapeutics.

What price target have analysts set for NEOS?

5 Wall Street analysts have issued 12 month price objectives for Neos Therapeutics' shares. Their predictions range from $12.00 to $20.00. On average, they expect Neos Therapeutics' stock price to reach $15.3333 in the next year. This suggests a possible upside of 151.4% from the stock's current price. View Analyst Ratings for Neos Therapeutics.

What is the consensus analysts' recommendation for Neos Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Neos Therapeutics stock?

Here are some recent quotes from research analysts about Neos Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis 1) On 01/10/18 NEOS announced that study findings for two of its ADHD medications, ER, were presented in three posters at the upcoming 2018 Annual Meeting of the American Professional Society of ADHD and Related Disorders (APSARD), on 02/20/18 PDL Biopharma (Not Covered) announced termination of interest in acquiring 02/26/18 NEOS announced the U.S. launch of Adzenys ER, making it NEOS’s third ADHD product launch in less than two years; 4) as discussed at the company’s analyst day in March of 2018, NEOS plans to advance its drug candidate for the treatment of nausea and vomiting into the clinic in 2H18 and to identify one additional branded product candidate in CNS or gastroenterology in 2018; and 5) as of 03/31/18 the company held $37.2MM in cash and cash equivalents." (5/9/2018)
  • 2. According to Zacks Investment Research, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. " (3/22/2018)

Who are some of Neos Therapeutics' key competitors?

Who are Neos Therapeutics' key executives?

Neos Therapeutics' management team includes the folowing people:
  • Dr. Vipin K. Garg, CEO, Pres & Director (Age 60)
  • Mr. Richard I. Eisenstadt, Chief Financial Officer (Age 60)
  • Mr. Thomas P. McDonnell, Chief Commercial Officer (Age 46)
  • Mr. Russ McMahen, VP of R&D
  • Dr. Carolyn R. Sikes Ph.D., VP of Clinical Affairs

When did Neos Therapeutics IPO?

(NEOS) raised $60 million in an initial public offering (IPO) on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

Has Neos Therapeutics been receiving favorable news coverage?

Headlines about NEOS stock have been trending somewhat positive recently, Accern reports. The research firm scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neos Therapeutics earned a daily sentiment score of 0.18 on Accern's scale. They also assigned headlines about the company an impact score of 46.16 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Neos Therapeutics?

Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neos Therapeutics' stock price today?

One share of NEOS stock can currently be purchased for approximately $6.10.

How big of a company is Neos Therapeutics?

Neos Therapeutics has a market capitalization of $184.13 million and generates $25.02 million in revenue each year. The company earns $-66,240,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Neos Therapeutics employs 138 workers across the globe.

How can I contact Neos Therapeutics?

Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]

MarketBeat Community Rating for Neos Therapeutics (NASDAQ NEOS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  243 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  423
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe NEOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.